["[Tab] Consolidated Statements of Cash Flows from Johnson & Johnson\n\n[Time]: 2023 [SEP]\n[row 0]: Cash flows from operating activities [SEP]\n[row 1]: Net earnings | $35,153 [SEP]\n[row 2]: Adjustments to reconcile net earnings to cash flows from operating activities: | [SEP]\n[row 3]: Depreciation and amortization of property and intangibles: | $7,486 [SEP]\n[row 4]: Stock based compensation | $1,162 [SEP]\n[row 5]: Asset write-downs | $1,295 [SEP]\n[row 6]: Charge for purchase of in-process research and development assets | $483 [SEP]\n[row 7]: Gain on KenVue separation | ($20,984) [SEP]\n[row 8]: Net gain on sale of assets/businesses | ($117) [SEP]\n[row 9]: Deferred tax provision | ($4,194) [SEP]\n[row 10]: Credit losses and accounts receivable allowances | \u2014 [SEP]\n[row 11]: Changes in assets and liabilities, net of effects from acquisitions and divestitures: | [SEP]\n[row 12]: Increase in accounts receivable | ($624) [SEP]\n[row 13]: Increase in inventories | ($1,323) [SEP]\n[row 14]: Increase in accounts payable and accrued liabilities | $2,346 [SEP]\n[row 15]: (Increase)/Decrease in other current and non-current assets | ($3,480) [SEP]\n[row 16]: Increase/(Decrease) in other current and non-current liabilities | $5,588 [SEP]\n[row 17]: Net cash flows from operating activities | $22,791 [SEP]\n[row 18]: Cash flows from investing activities [SEP]\n[row 19]: Additions to property, plant and equipment | ($4,543) [SEP]\n[row 20]: Proceeds from the disposal of assets/businesses, net | $358 [SEP]\n[row 21]: Acquisitions, net of cash acquired | \u2014 [SEP]\n[row 22]: Purchases of in-process research and development assets | ($470) [SEP]\n[row 23]: Purchases of investments | ($10,096) [SEP]\n[row 24]: Sales of investments | $19,390 [SEP]\n[row 25]: Credit support agreements activity, net | ($2,963) [SEP]\n[row 26]: Other (including capitalized licenses and milestones) | ($12) [SEP]\n[row 27]: Net cash from/(used) by investing activities | $878 [SEP]\n[row 28]: Cash flows from financing activities [SEP]\n[row 29]: Dividends to shareholders | ($11,770) [SEP]\n[row 30]: Repurchase of common stock | ($5,054) [SEP]\n[row 31]: Proceeds from short-term debt | $13,743 [SEP]\n[row 32]: Repayment of short-term debt | ($22,973) [SEP]\n[row 33]: Repayment of long-term debt | ($1,551) [SEP]\n[row 34]: Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | $1,094 [SEP]\n[row 35]: Credit support agreements activity, net | ($219) [SEP]\n\n[Time]: 2022 [SEP]\n[row 0]: Cash flows from operating activities [SEP]\n[row 1]: Net earnings | $17,941 [SEP]\n[row 2]: Adjustments to reconcile net earnings to cash flows from operating activities: | [SEP]\n[row 3]: Depreciation and amortization of property and intangibles: | $6,970 [SEP]\n[row 4]: Stock based compensation | $1,138 [SEP]\n[row 5]: Asset write-downs | $1,216 [SEP]\n[row 6]: Charge for purchase of in-process research and development assets | \u2014 [SEP]\n[row 7]: Gain on KenVue separation | \u2014 [SEP]\n[row 8]: Net gain on sale of assets/businesses | ($380) [SEP]\n[row 9]: Deferred tax provision | ($1,663) [SEP]\n[row 10]: Credit losses and accounts receivable allowances | ($17) [SEP]\n[row 11]: Changes in assets and liabilities, net of effects from acquisitions and divestitures: | [SEP]\n[row 12]: Increase in accounts receivable | ($1,290) [SEP]\n[row 13]: Increase in inventories | ($2,527) [SEP]\n[row 14]: Increase in accounts payable and accrued liabilities | $1,098 [SEP]\n[row 15]: (Increase)/Decrease in other current and non-current assets | $687 [SEP]\n[row 16]: Increase/(Decrease) in other current and non-current liabilities | ($1,979) [SEP]\n[row 17]: Net cash flows from operating activities | $21,194 [SEP]\n[row 18]: Cash flows from investing activities [SEP]\n[row 19]: Additions to property, plant and equipment | ($4,009) [SEP]\n[row 20]: Proceeds from the disposal of assets/businesses, net | $543 [SEP]\n[row 21]: Acquisitions, net of cash acquired | ($17,652) [SEP]\n[row 22]: Purchases of in-process research and development assets | \u2014 [SEP]\n[row 23]: Purchases of investments | ($32,384) [SEP]\n[row 24]: Sales of investments | $41,609 [SEP]\n[row 25]: Credit support agreements activity, net | ($249) [SEP]\n[row 26]: Other (including capitalized licenses and milestones) | ($229) [SEP]\n[row 27]: Net cash from/(used) by investing activities | ($12,371) [SEP]\n[row 28]: Cash flows from financing activities [SEP]\n[row 29]: Dividends to shareholders | ($11,682) [SEP]\n[row 30]: Repurchase of common stock | ($6,035) [SEP]\n[row 31]: Proceeds from short-term debt | $16,134 [SEP]\n[row 32]: Repayment of short-term debt | ($6,550) [SEP]\n[row 33]: Repayment of long-term debt | ($2,134) [SEP]\n[row 34]: Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | $1,329 [SEP]\n[row 35]: Credit support agreements activity, net | ($28) [SEP]\n\n[Time]: 2021 [SEP]\n[row 0]: Cash flows from operating activities [SEP]\n[row 1]: Net earnings | $20,878 [SEP]\n[row 2]: Adjustments to reconcile net earnings to cash flows from operating activities: | [SEP]\n[row 3]: Depreciation and amortization of property and intangibles: | $7,390 [SEP]\n[row 4]: Stock based compensation | $1,135 [SEP]\n[row 5]: Asset write-downs | $989 [SEP]\n[row 6]: Charge for purchase of in-process research and development assets | \u2014 [SEP]\n[row 7]: Gain on KenVue separation | \u2014 [SEP]\n[row 8]: Net gain on sale of assets/businesses | ($617) [SEP]\n[row 9]: Deferred tax provision | ($2,079) [SEP]\n[row 10]: Credit losses and accounts receivable allowances | ($48) [SEP]\n[row 11]: Changes in assets and liabilities, net of effects from acquisitions and divestitures: | [SEP]\n[row 12]: Increase in accounts receivable | ($2,402) [SEP]\n[row 13]: Increase in inventories | ($1,248) [SEP]\n[row 14]: Increase in accounts payable and accrued liabilities | $2,437 [SEP]\n[row 15]: (Increase)/Decrease in other current and non-current assets | ($1,964) [SEP]\n[row 16]: Increase/(Decrease) in other current and non-current liabilities | ($1,061) [SEP]\n[row 17]: Net cash flows from operating activities | $23,410 [SEP]\n[row 18]: Cash flows from investing activities [SEP]\n[row 19]: Additions to property, plant and equipment | ($3,652) [SEP]\n[row 20]: Proceeds from the disposal of assets/businesses, net | $711 [SEP]\n[row 21]: Acquisitions, net of cash acquired | \u2014 [SEP]\n[row 22]: Purchases of in-process research and development assets | ($60) [SEP]\n[row 23]: Purchases of investments | ($30,394) [SEP]\n[row 24]: Sales of investments | $25,006 [SEP]\n[row 25]: Credit support agreements activity, net | $214 [SEP]\n[row 26]: Other (including capitalized licenses and milestones) | ($508) [SEP]\n[row 27]: Net cash from/(used) by investing activities | ($8,683) [SEP]\n[row 28]: Cash flows from financing activities [SEP]\n[row 29]: Dividends to shareholders | ($11,032) [SEP]\n[row 30]: Repurchase of common stock | ($3,456) [SEP]\n[row 31]: Proceeds from short-term debt | $1,997 [SEP]\n[row 32]: Repayment of short-term debt | \u2014 [SEP]\n[row 33]: Repayment of long-term debt | $2 [SEP]\n[row 34]: Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | $5 [SEP]\n[row 35]: Credit support agreements activity, net | \u2014 [SEP]"]